1. Home
  2. FUND vs SLGL Comparison

FUND vs SLGL Comparison

Compare FUND & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FUND

Sprott Focus Trust Inc.

HOLD

Current Price

$9.97

Market Cap

294.2M

Sector

Finance

ML Signal

HOLD

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

HOLD

Current Price

$85.34

Market Cap

255.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUND
SLGL
Founded
1988
1997
Country
Canada
Israel
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
294.2M
255.2M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
FUND
SLGL
Price
$9.97
$85.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$110.00
AVG Volume (30 Days)
35.1K
27.1K
Earning Date
01-01-0001
05-22-2026
Dividend Yield
6.64%
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$223.84
P/E Ratio
$10.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.50
$11.82
52 Week High
$10.47
$97.97

Technical Indicators

Market Signals
Indicator
FUND
SLGL
Relative Strength Index (RSI) 57.38 55.78
Support Level $9.87 $67.53
Resistance Level $10.06 $95.31
Average True Range (ATR) 0.15 6.31
MACD 0.03 0.23
Stochastic Oscillator 71.95 47.85

Price Performance

Historical Comparison
FUND
SLGL

About FUND Sprott Focus Trust Inc.

Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.

Share on Social Networks: